Why This Matters: Without action, Canada becomes a less attractive market, access to new treatments is even further delayed, and our health, economic, and national security are weakened.
Summary: Global drug policy changes are reshaping where companies invest and launch new medicines. Dr. Bettina Hamelin, President & CEO of Innovative Medicines Canada, argues that Canada must address its innovation gap by creating an environment that supports research, investment, and access to breakthrough treatments.